COTELLIC + ZELBORAF
Therapy
The combination of cobimetinib and vemurafenib (Genentech) is used in tumors with actionable BRAF mutations.
Approvals
3
Indications
1
Biomarkers
1
Mapped tests
3
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and COTELLIC + ZELBORAF. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where COTELLIC + ZELBORAF is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Melanoma Solid Tumor · Melanoma | BRAF
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for COTELLIC + ZELBORAF.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering COTELLIC + ZELBORAF for eligible patients.
Test
cobas 4800 BRAF V600 Mutation Test
Roche Molecular Systems, Inc. (Roche Diagnostics)
Method
PCR
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
MI Cancer Seek (MCS)
Caris Life Sciences
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →